SML3119

TPI-1

≥98% (HPLC), SHP-1 catalytic domain inhibitor, powder

• Synonym(e): 2-(2,5-Dichloro-phenyl)-[1,4]benzoquinone; 2-(2?,5?-Dichlorophenyl)-1,4-benzoquinone, 2-(2,5-Dichlorophenyl)-2,5-cyclohexadiene-1,4-dione, TPI 1, TPI-1, TPI1
• Empirische Formel (Hill-System): C₁₂H₆Cl₂O₂
• CAS-Nummer: 79756-69-7
• Molekulargewicht: 253.08
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD00448731
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: SHP1 Inhibitor, TPI-1, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: O=C1C=CC(C(C2=C(C=CC(Cl)=C2)Cl)=C1)=O
• InChI: 1S/C12H6Cl2O2/c13-7-1-3-11(14)9(5-7)10-6-8(15)2-4-12(10)16/h1-6H
• InChI key: ZKHFYORNAYYOTM-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

TPI-1 is an orally bioavailable, noncytotoxic benzoquinone compound that acts as a potent irreversible inhibitor of SHP-1 (Src homology region 2 domain-containing phosphatase 1) catalytic domain (IC50 ~ 40 nM or 0.01 μg/ml) with selectivity over SHP-2 (IC50 ~ 0.1 μg/ml), MKP1 (IC50 > 1 μg/ml) and CD45. TPI-1 potently induces mouse and human primary IFN-g+ cells both in vitro and in vivo. Effectively inhibits B16 melanoma tumors in mice (1 or 3 mg/kg, s.c., daily) and prolong the survival. TPI-1 is shown to be 50-fold more effective than sodium stibogluconate in cell-based assays and may non-specifically react with cysteine residues.

orally bioavailable, noncytotoxic benzoquinone compound that acts as a potent and selective irreversible inhibitor of SHP-1 catalytic domain

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable